“Game-Changer” Breast Cancer Drug News Triggers H.C. Wainwright Upgrade for Celcuity
Celcuity’s drug showed strong results in breast cancer, boosting survival and raising hopes it could become a new standard treatment.
/ 4 items
#CELC↓
Celcuity Shares Surge After Gedatolisib Shows 76% Reduction in Disease Progression
Celcuity shares jump 45% after Phase 3 trial shows gedatolisib significantly improves survival in HR+/HER2- breast cancer patients. Analysts raise price target to $95.
Guggenheim's Buy Rating for Celcuity and Gedatolisib Potential
Financial firm Guggenheim gave Celcuity a Buy rating, predicting massive sales for its breast cancer drug, Gedatolisib.
Celcuity's Gedatolisib Shows Unprecedented Breast Cancer Trial Results
Phase 3 VIKTORIA-1 trial shows gedatolisib triplet slashed disease progression risk by 76% in HR+/HER2- advanced breast cancer, with favorable safety.